The post Hyperliquid Strategies Launches $30M Stock Buyback Program appeared on BitcoinEthereumNews.com. In Brief Hyperliquid Strategies to repurchase up to $30M of its stock over 12 months. The buyback aims to increase shareholders’ exposure to the HYPE token ecosystem. The move follows Hyperliquid’s recent Nasdaq listing and completed SPAC merger. Hyperliquid Strategies Inc. (NASDAQ: PURR) has announced a stock buyback program worth up to $30 million over 12 months. The initiative allows repurchases through open market transactions, private deals, or other methods compliant with federal securities laws. The company stated that actual repurchase timing and quantity will depend on market conditions and internal decisions. The program may be extended, paused, or canceled at the company’s discretion without prior notice. Hyperliquid Strategies Inc ( $PURR) Announces $30 million Stock Repurchase Program.Par value $0.01 per share. The stock repurchase program will be in place for up to 12 months. pic.twitter.com/rkzOusi9n7 — Hyperliquid News (@HyperliquidNews) December 8, 2025 Hyperliquid Strategies aims to boost per-share exposure to HYPE, the native token of the Hyperliquid ecosystem. The company continues focusing on maximizing shareholder value through active treasury management. Program Follows Strategic Merger and Public Market Debut The buyback plan comes shortly after the company’s merger between Sonnet BioTherapeutics and SPAC Rorschach was finalized on December 2. Shares of PURR began trading on Nasdaq on December 3, and the stock currently trades near $3.64. Hyperliquid Strategies is one of the largest holders of the HYPE token, valued near $29 as of the latest data. The company previously committed to deploying its HYPE holdings into staking and DeFi strategies to support long-term performance. The firm is supported by investors including D1 Capital, Galaxy Digital, and Pantera Capital, and chaired by former Barclays CEO Bob Diamond. It filed an S-1 to raise up to $1 billion to fund its digital asset treasury activities. Unlike other crypto firms, Hyperliquid Strategies did… The post Hyperliquid Strategies Launches $30M Stock Buyback Program appeared on BitcoinEthereumNews.com. In Brief Hyperliquid Strategies to repurchase up to $30M of its stock over 12 months. The buyback aims to increase shareholders’ exposure to the HYPE token ecosystem. The move follows Hyperliquid’s recent Nasdaq listing and completed SPAC merger. Hyperliquid Strategies Inc. (NASDAQ: PURR) has announced a stock buyback program worth up to $30 million over 12 months. The initiative allows repurchases through open market transactions, private deals, or other methods compliant with federal securities laws. The company stated that actual repurchase timing and quantity will depend on market conditions and internal decisions. The program may be extended, paused, or canceled at the company’s discretion without prior notice. Hyperliquid Strategies Inc ( $PURR) Announces $30 million Stock Repurchase Program.Par value $0.01 per share. The stock repurchase program will be in place for up to 12 months. pic.twitter.com/rkzOusi9n7 — Hyperliquid News (@HyperliquidNews) December 8, 2025 Hyperliquid Strategies aims to boost per-share exposure to HYPE, the native token of the Hyperliquid ecosystem. The company continues focusing on maximizing shareholder value through active treasury management. Program Follows Strategic Merger and Public Market Debut The buyback plan comes shortly after the company’s merger between Sonnet BioTherapeutics and SPAC Rorschach was finalized on December 2. Shares of PURR began trading on Nasdaq on December 3, and the stock currently trades near $3.64. Hyperliquid Strategies is one of the largest holders of the HYPE token, valued near $29 as of the latest data. The company previously committed to deploying its HYPE holdings into staking and DeFi strategies to support long-term performance. The firm is supported by investors including D1 Capital, Galaxy Digital, and Pantera Capital, and chaired by former Barclays CEO Bob Diamond. It filed an S-1 to raise up to $1 billion to fund its digital asset treasury activities. Unlike other crypto firms, Hyperliquid Strategies did…

Hyperliquid Strategies Launches $30M Stock Buyback Program

In Brief

  • Hyperliquid Strategies to repurchase up to $30M of its stock over 12 months.
  • The buyback aims to increase shareholders’ exposure to the HYPE token ecosystem.
  • The move follows Hyperliquid’s recent Nasdaq listing and completed SPAC merger.


Hyperliquid Strategies Inc. (NASDAQ: PURR) has announced a stock buyback program worth up to $30 million over 12 months. The initiative allows repurchases through open market transactions, private deals, or other methods compliant with federal securities laws.

The company stated that actual repurchase timing and quantity will depend on market conditions and internal decisions. The program may be extended, paused, or canceled at the company’s discretion without prior notice.

Hyperliquid Strategies aims to boost per-share exposure to HYPE, the native token of the Hyperliquid ecosystem. The company continues focusing on maximizing shareholder value through active treasury management.

Program Follows Strategic Merger and Public Market Debut

The buyback plan comes shortly after the company’s merger between Sonnet BioTherapeutics and SPAC Rorschach was finalized on December 2. Shares of PURR began trading on Nasdaq on December 3, and the stock currently trades near $3.64.

Hyperliquid Strategies is one of the largest holders of the HYPE token, valued near $29 as of the latest data. The company previously committed to deploying its HYPE holdings into staking and DeFi strategies to support long-term performance.

The firm is supported by investors including D1 Capital, Galaxy Digital, and Pantera Capital, and chaired by former Barclays CEO Bob Diamond. It filed an S-1 to raise up to $1 billion to fund its digital asset treasury activities.

Unlike other crypto firms, Hyperliquid Strategies did not raise traditional venture funding. Instead, HYPE was airdropped to early users, with remaining supply allocated to founders and the Hyper Foundation.

The protocol behind HYPE is now the largest decentralized perpetuals DEX by volume. Competitors like Aster and Liquid have only recently begun to gain market share.

With the buyback initiative, Hyperliquid joins other digital asset treasuries in supporting its equity during market uncertainty. The company continues positioning itself as a key bridge between token exposure and U.S. capital markets.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Source: https://coincu.com/hype/hyperliquid-strategies-launches-30m/

Market Opportunity
Hyperliquid Logo
Hyperliquid Price(HYPE)
$29.78
$29.78$29.78
-4.85%
USD
Hyperliquid (HYPE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26